Pds Biotechnology Corp (PDSB) Stock Price, Quote & News

Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T c...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 208 3343

Website: www.pdsbiotech.com

Address:

303A College Road East, Princeton, United States

topstockalerts May. 14 at 2:07 AM

$PDSB the chart is developing in a very healthy way.

0 · Reply

Ncossey May. 14 at 1:36 AM

$PDSB where do think this will land tomorrow? No BS paid folks. Just real feed back. The price analysis of 15 on the top end sounds amazing..but is it factoring a reverse split?

0 · Reply

costap May. 14 at 12:48 AM

$PDSB oh my lands finally

2 · Reply

Mr_Charlie May. 13 at 10:20 PM

$PDSB looks like a ping pong between 1 and 1.30

0 · Reply

Llamalamb2921 May. 13 at 9:59 PM

$PDSB Frank throwing around BLA talk this morning like the application is already being written.

1 · Reply

Stockman824 May. 13 at 8:22 PM

$PDSB owned PDSB for a longtime but sold out a while ago. Just wishing you all immense success, even though I’m no longer a stock owner. Hope you all make a ton of money $$$ and that they change the oncology field!!

3 · Reply

KG1816 May. 13 at 7:54 PM

$PDSB hopefully it blasts through $1.36 and finds a home well above that before any big / significant news.

0 · Reply

JohntyCT May. 13 at 7:31 PM

$PDSB most days I regret not having stops in place on this stock. Today is not one of those days!

0 · Reply

Ontherag May. 13 at 7:24 PM

$PDSB market starting think Frank has a partner lined up

0 · Reply

wyoming2020 May. 13 at 7:02 PM

$PDSB still here

1 · Reply

PDS Biotechnology Earnings Call Transcript: Q1 2026

May 13, 2026, 7:00 AM EDT - 17 hours ago

PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

May 6, 2026, 8:00 AM EDT - 7 days ago

PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results

2026-04-15T13:37:04.000Z - 4 weeks ago

PDS Biotechnology announces positive Phase 2 trial data for PDS01ADC

Apr 15, 2026, 8:45 AM EDT - 4 weeks ago

PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

Mar 30, 2026, 8:00 AM EDT - 6 weeks ago

PDS Biotechnology Earnings Call Transcript: Q4 2025

2026-03-30T11:05:14.000Z - 6 weeks ago

Options Volatility and Implied Earnings Moves Today, March 30, 2026

CBAT DFDV FRMI NMRA SGML SPCE SPRU

Mar 30, 2026, 7:00 AM EDT - 6 weeks ago

PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Mar 24, 2026, 4:05 PM EDT - 7 weeks ago

PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

Feb 20, 2026, 8:30 AM EST - 2 months ago

PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

Jan 28, 2026, 8:45 AM EST - 3 months ago

PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

Jan 22, 2026, 8:45 AM EST - 3 months ago

PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

Jan 9, 2026, 8:45 AM EST - 4 months ago

PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

Dec 9, 2025, 8:00 AM EST - 5 months ago

PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

Dec 2, 2025, 8:30 AM EST - 5 months ago

PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

Nov 13, 2025, 8:00 AM EST - 6 months ago

PDS Biotechnology Earnings Call Transcript: Q3 2025

Nov 13, 2025, 7:30 AM EST - 6 months ago

PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Nov 11, 2025, 3:31 PM EST - 6 months ago

PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

Nov 10, 2025, 8:30 AM EST - 6 months ago

PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

Oct 30, 2025, 8:00 AM EDT - 6 months ago

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 29, 2025, 8:37 AM EDT - 7 months ago

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Sep 18, 2025, 8:45 AM EDT - 8 months ago

PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population

Sep 2, 2025, 8:00 AM EDT - 9 months ago

PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 8:30 AM EDT - 9 months ago

PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer

Aug 13, 2025, 8:00 AM EDT - 9 months ago

PDS Biotechnology Earnings Call Transcript: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Aug 6, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 10 months ago

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Jun 17, 2025, 12:00 PM EDT - 11 months ago

PDS Biotechnology Transcript: Status Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Jun 2, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune® HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Transcript: Study Update

May 22, 2025, 5:26 PM EDT - 1 year ago

PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 21, 2025, 5:20 PM EDT - 1 year ago

PDS Biotechnology Transcript: A.G.P. Virtual Annual Healthcare Company Showcase

May 20, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q1 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update

May 9, 2025, 4:05 PM EDT - 1 year ago

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

May 7, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results

Apr 23, 2025, 10:16 AM EDT - 1 year ago

PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 16, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting

Apr 8, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q4 2024

Mar 27, 2025, 7:30 AM EDT - 1 year ago

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Mar 25, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference

Mar 18, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results

Mar 13, 2025, 2:30 PM EDT - 1 year ago

PDS Biotechnology Transcript: Life Sciences Virtual Investor Conference

Mar 13, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer

Mar 11, 2025, 8:00 AM EDT - 1 year ago

PDS Biotech Leadership to Participate in March Conferences

Mar 7, 2025, 8:45 AM EST - 1 year ago

PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Feb 27, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 26, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology

Feb 24, 2025, 8:00 AM EST - 1 year ago

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research

Feb 20, 2025, 8:00 AM EST - 1 year ago

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Dec 3, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET

Nov 14, 2024, 8:30 AM EST - 1 year ago

PDS Biotechnology Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Oct 2, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation

Sep 9, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

Sep 3, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 8:00 AM EDT - 1 year ago

PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024

topstockalerts May. 14 at 2:07 AM

$PDSB the chart is developing in a very healthy way.

0 · Reply

Ncossey May. 14 at 1:36 AM

$PDSB where do think this will land tomorrow? No BS paid folks. Just real feed back. The price analysis of 15 on the top end sounds amazing..but is it factoring a reverse split?

0 · Reply

costap May. 14 at 12:48 AM

$PDSB oh my lands finally

2 · Reply

Mr_Charlie May. 13 at 10:20 PM

$PDSB looks like a ping pong between 1 and 1.30

0 · Reply

Llamalamb2921 May. 13 at 9:59 PM

$PDSB Frank throwing around BLA talk this morning like the application is already being written.

1 · Reply

Stockman824 May. 13 at 8:22 PM

3 · Reply

KG1816 May. 13 at 7:54 PM

$PDSB hopefully it blasts through $1.36 and finds a home well above that before any big / significant news.

0 · Reply

JohntyCT May. 13 at 7:31 PM

$PDSB most days I regret not having stops in place on this stock. Today is not one of those days!

0 · Reply

Ontherag May. 13 at 7:24 PM

$PDSB market starting think Frank has a partner lined up

0 · Reply

wyoming2020 May. 13 at 7:02 PM

$PDSB still here

1 · Reply

alphabetsop May. 13 at 6:20 PM

$PDSB I think we all know what's coming. Just need to wait for the announcement.😀

1 · Reply

MarketBeat May. 13 at 6:11 PM

https://marketbeat.com/a/8652819/ $PDSB PDS Biotechnology Q1 Earnings Call Highlights

0 · Reply

Merlintrader May. 13 at 6:06 PM

$TYRA Three Biotech Stocks With Fresh May 13 Updates: $TYRA, $SPRB and $PDSB https://www.merlintrader.com/biotech-updates-tyra-sprb-pdsb-may2026/

0 · Reply

Marcino11 May. 13 at 6:05 PM

$PDSB Biontech was named in the call. Any chance for them taking an interest in PDSB and are they a competitor?

2 · Reply

Ontherag May. 13 at 5:04 PM

$PDSB Why was the company in a rush to report q1 earnings, any ideas?

2 · Reply

Ontherag May. 13 at 4:43 PM

$PDSB some big bids incoming…giant wall at 1.35

0 · Reply

Kosmokrat May. 13 at 4:32 PM

$PDSB They will need more capital during 2026, and the next big catalyst will probably be any update on any of their clinical studies. When can we expect that?

0 · Reply

Mr_Charlie May. 13 at 2:58 PM

$PDSB it will be a miracle if this company reaches Ph3 clinical trial end. Maybe we get lucky and someone buy it before.

0 · Reply

EarningsInsider May. 13 at 12:46 PM

https://www.marketbeat.com/earnings/reports/2026-5-13-pds-biotechnology-co-stock/ $PDSB PDS Biotechnology Earnings Transcript

0 · Reply

StocktwitsEarnings May. 13 at 12:08 PM

$PDSB Q1 '26 Earnings Results & Recap Reported GAAP EPS of -$0.13 up 38.10% YoY

0 · Reply

Mr_Charlie May. 13 at 12:02 PM

$PDSB a lot of bla bla bla which means nothing. We will have to wait another year to ear anything meaninful. For the moment we hold hold hold.

1 · Reply

dvice2 May. 13 at 11:22 AM

$PDSB V-003 not even restarted yet 😂

1 · Reply

Market Cap	59.84M
Revenue (ttm)	0.00
Net Income (ttm)	-34.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.27

Volume	1,422,600
Avg Vol	855,594
Day's Range	N/A - N/A
Shares Out	54.40M
Stochastic %K	95%
Beta	1.51
Analysts	Strong Sell
Price Target	$7.50